Cellectis (CLLS) Misses Q1 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cellectis Reports First Quarter 2016 Financial Results
May 11, 2016 5:00 PM EDT- Initiated UCART123 GMP production concept
- Secured strategic supply of key materials for GMP manufacturing
- Strong cash position of $315 million (276 million) as of March, 31 2016
NEW YORK--(BUSINESS WIRE)--
Regulatory News:
Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced its results for the three-month period ended March 31, 2016.
We are excited to monitor the results presented by... More
